RATIONALE: Although inhaled corticosteroids (ICS) are considered first line controller therapy in children with persistent asthma, heterogeneity of the ICS response can be an important clinical problem. The purpose of this study is to determine the value of the bronchodilator response (BDR) in identifying the ICS responder and establish the optimal BDR cut-point that could be particularly useful in the clinic setting when baseline spirometry is normal. METHODS: Mexican American asthmatic children, 5-18 years, with normal baseline spirometry who required low dose (step 2), or medium dose (step 3) ICS therapy were evaluated by skin prick test for atopy, and pre- and post-bronchodilator spirometry. ICS responders were defined by a ≥7.5% improvement in the FEV1 following 4-6 weeks of therapy. The optimal cut-point was determined by Receiver Operator Characteristic (ROC) curves as the best balance between sensitivity and specificity. RESULTS: There were 34.8% of the 132 study patients who were ICS responders. ROC curves showed the BDR ≥10% to be an optimal cut-point with sensitivity 46%, specificity 76%, positive predictive value (PPV) 50%, and negative predictive value (NPV) 72%. Atopic females with a BDR ≥10% had a PPV of 73%. CONCLUSIONS: The composite phenotype of female gender, atopic, and the BDR of ≥10% identified 73% as ICS responders compared to 50% in our overall population with a BDR of ≥10% alone, with minimal false positives. We suggest that the BDR in conjunction with gender and atopic status be considered as potentially useful predictors of the ICS responder, particularly when baseline spirometry is normal.
RATIONALE: Although inhaled corticosteroids (ICS) are considered first line controller therapy in children with persistent asthma, heterogeneity of the ICS response can be an important clinical problem. The purpose of this study is to determine the value of the bronchodilator response (BDR) in identifying the ICS responder and establish the optimal BDR cut-point that could be particularly useful in the clinic setting when baseline spirometry is normal. METHODS: Mexican American asthmatic children, 5-18 years, with normal baseline spirometry who required low dose (step 2), or medium dose (step 3) ICS therapy were evaluated by skin prick test for atopy, and pre- and post-bronchodilator spirometry. ICS responders were defined by a ≥7.5% improvement in the FEV1 following 4-6 weeks of therapy. The optimal cut-point was determined by Receiver Operator Characteristic (ROC) curves as the best balance between sensitivity and specificity. RESULTS: There were 34.8% of the 132 study patients who were ICS responders. ROC curves showed the BDR ≥10% to be an optimal cut-point with sensitivity 46%, specificity 76%, positive predictive value (PPV) 50%, and negative predictive value (NPV) 72%. Atopic females with a BDR ≥10% had a PPV of 73%. CONCLUSIONS: The composite phenotype of female gender, atopic, and the BDR of ≥10% identified 73% as ICS responders compared to 50% in our overall population with a BDR of ≥10% alone, with minimal false positives. We suggest that the BDR in conjunction with gender and atopic status be considered as potentially useful predictors of the ICS responder, particularly when baseline spirometry is normal.
Authors: Stanley P Galant; Hirsh D Komarow; Hye-Won Shin; Salman Siddiqui; Brian J Lipworth Journal: Ann Allergy Asthma Immunol Date: 2017-06 Impact factor: 6.347
Authors: John M Brehm; Sima K Ramratnam; Sze Man Tse; Damien C Croteau-Chonka; Maria Pino-Yanes; Christian Rosas-Salazar; Augusto A Litonjua; Benjamin A Raby; Nadia Boutaoui; Yueh-Ying Han; Wei Chen; Erick Forno; Anna L Marsland; Nicole R Nugent; Celeste Eng; Angel Colón-Semidey; María Alvarez; Edna Acosta-Pérez; Melissa L Spear; Fernando D Martinez; Lydiana Avila; Scott T Weiss; Manuel Soto-Quiros; Carole Ober; Dan L Nicolae; Kathleen C Barnes; Robert F Lemanske; Robert C Strunk; Andrew Liu; Stephanie J London; Frank Gilliland; Patrick Sleiman; Michael March; Hakon Hakonarson; Qing Ling Duan; Jay K Kolls; Gregory K Fritz; Donglei Hu; Negar Fani; Jennifer S Stevens; Lynn M Almli; Esteban G Burchard; Jaemin Shin; Elizabeth L McQuaid; Kerry Ressler; Glorisa Canino; Juan C Celedón Journal: Am J Respir Crit Care Med Date: 2015-07-01 Impact factor: 21.405